CGD in the News
HIV Prevention Gel Hits Snag: Money (New York Times)
September 7, 2010
The New York Times quotes senior fellow Mead Over on the cost of ARVs.
From the article:
Experts say investing in AIDS prevention is fiscally far preferable to the costs for lifelong treatment. Mead Over, a health economist at the Center for Global Development, says that providing antiretroviral therapy to the five million people with AIDS in Africa already receiving it will cost $72 billion over the next four decades. That amount rises to $225 billion if the number of people on treatment continues to grow.
“Donors should not be nickel and diming this research because by spending only $100 million they have a prospect of saving billions of dollars in treatment costs,” Mr. Over said.
